Asian flu vaccine provider Adimmune is continuing with patient enrolment for its Phase III trial of Quadrivalent Influenza Vaccine in Europe.

The quadrivalent flu vaccines are designed to protect against four different flu viruses: two influenza A and two influenza B.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

With the number of patients recruited crossing 1,000, the Phase III trial is the largest clinical trial held in
Europe, initiated by a Taiwanese vaccine company and is considered as a milestone for Adimmune to begin selling its own-brand product in Europe.

"The quadrivalent flu vaccines are designed to protect against four different flu viruses: two influenza A and two influenza B."

Enrolment for the study is expected to close by the end of this year.

Meanwhile, strategic collaboration between Adimmune and Techdow Pharmaceutical has obtained approval to manufacture Enoxaparin Sodium pre-filled syringes in Poland and other sites within the European Union (EU).

See Also:

The collaboration was initiated in 2013, under which Techdow provided Enoxaparin API, while Adimmune provides a pre-filled syringe filling service and ships to Europe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Europe has strong demand for enoxaparin sodium and Adimmune expects the usage rate of its PFS production line to quickly increase after mass production.